


Figure 1 - Placebo adjusted scores in phase III trials in biologics-naïve PSA



Source: Tofacitinib 5mg BID at 12w, OPAL BROADEN, Mease, 2017; Otezla 30mg BID at 16w, ACTIVE, Nash, 2018; Humira 40mg q2w at 12w, OPAL BROADEN, Mease, 2017; Stelara 45mg at 24w, PSUMMIT1, McInnes, 2013; Cosentyx 300mg at 16w, FUTURE 5, Mease 2018; Taltz 80mg 12w